Regeneron earns mid-stage win for higher dose of Eylea, hoping to refresh its sales pitch

Regeneron has made its name on the blockbuster success of eye drug Eylea, but with the aging drug facing a raft of competitors the drugmaker is looking for ways to keep its sales pitch fresh. And researchers are blazing a fresh trail on that front with new mid-stage data out today.